All Stories

  1. TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients
  2. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications
  3. Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
  4. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer
  5. CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications
  6. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology
  7. Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
  8. TargetedO-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours
  9. Reference Genes for Addressing Gene Expression of Bladder Cancer Cell Models under Hypoxia: A Step Towards Transcriptomic Studies
  10. IL6-174G > C genetic polymorphism influences antidepressant treatment outcome
  11. Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension
  12. The role of IL18-607C > A and IL18-137G > C promoter polymorphisms in antidepressant treatment phenotypes: A preliminary report
  13. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics
  14. FAS -670A>G genetic polymorphism Is associated with Treatment Resistant Depression
  15. New trends in guided nanotherapies for digestive cancers: A systematic review
  16. The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population
  17. P53 and Cancer-Associated Sialylated Glycans Are Surrogate Markers of Cancerization of the Bladder Associated with Schistosoma haematobium Infection
  18. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure11The first author has a PhD Grant (SFRH/BD/43399/2008) and J.A.F. has a Postdoctoral Grant (SFRH/BPD/66288/2009) from ...
  19. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer
  20. Common Genetic Polymorphisms in the ABCB1 Gene Are Associated with Risk of Major Depressive Disorder in Male Portuguese Individuals
  21. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy
  22. Frequency of TERT promoter mutations in human cancers
  23. Overexpression of tumour-ssociated carbohydrate antigen sialyl-Tn in advanced bladder tumours
  24. Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
  25. CIS is a surrogate marker of genetic instability and field carcinogenesis in the urothelial mucosa
  26. IL-4 and TNF-α Polymorphisms Are Associated with Risk of Multiple Superficial Tumors or Carcinoma in situ Development
  27. Association between FAS polymorphism and prostate cancer development